title: EVALUATION OF ANTIVIRAL THERAPY TREATMENT FOR LIVER CIRRHOSIS CAUSED BY CHRONIC HEPATITIS C AND HEPATITIS C BY 31P-MRS, BASED ON METABOLITE DETECTION.
abstract: This study discusses the application of magnetic resonance spectrum (MRS) to evaluate the efficacy of antiviral therapy in the treatment of liver cirrhosis caused by chronic hepatitis C and hepatitis C, based on metabolite detection. A total of 54 patients with liver cirrhosis caused by chronic hepatitis C and hepatitis C were selected and divided into treatment group and control group. 31P-MRS imaging was carried out on patients in the two groups both before receiving antiviral treatment and 6 months after treatment to compare the change of metabolite ratio (PE+PC)/(GPE+GPC). It was revealed that no statistically significant difference was found in the comparison of (PC+PE)/(GPC+GPE) ratio in the two groups before treatment, but the difference was found 6 months after treatment; ratio of (PC+PE)/ (GPC+GPE) in the treatment group distinctly decreased 6 months after treatment compared to before treatment, with a statistically significant difference, while the control group had no remarkable change or statistical significance. Moreover, 32 patients were found with sustained virus response to antiviral therapy. Of these, 25 patients possessed a decreased ratio of (PC+PE)/ (GPC+GPE), 4 remained without change and 3 had a slightly increased ratio after antiviral treatment. Of 12 patients with no response, 1 had a decreased ratio of (PC+PE)/ (GPC+GPE), 2 remained without change and 9 had a slightly increased ratio. The differences were all statistically significant in comparison of the two groups. 31P-MRS is thought to be effective for evaluating the efficacy of antiviral therapy through non-invasive detection of liver energy metabolism.
authors.affiliation: Department of Infectious Diseases, the First Affiliated Hospital, Zhengzhou University, Zhengzhou, Henan, China.
authors.forename: J S
authors.initials: JS
authors.lastname: Gu
authors.affiliation: Department of Infectious Diseases, the First Affiliated Hospital, Zhengzhou University, Zhengzhou, Henan, China.
authors.forename: R R
authors.initials: RR
authors.lastname: Sun
authors.affiliation: Department of Infectious Diseases, the First Affiliated Hospital, Zhengzhou University, Zhengzhou, Henan, China.
authors.forename: S
authors.initials: S
authors.lastname: Shen
authors.affiliation: Department of Infectious Diseases, the First Affiliated Hospital, Zhengzhou University, Zhengzhou, Henan, China.
authors.forename: Z J
authors.initials: ZJ
authors.lastname: Yu
mesh_terms: D000255:Adenosine Triphosphate / Q000032:analysis*; D000328:Adult; D000368:Aged; D000998:Antiviral Agents / Q000627:therapeutic use*; D016903:Drug Monitoring / Q000379:methods*; D004983:Ethanolamines / Q000032:analysis*; D005260:Female; D005997:Glycerylphosphorylcholine / Q000032:analysis*; D016174:Hepacivirus / Q000302:isolation & purification; D006526:Hepatitis C / Q000188:drug therapy* / Q000378:metabolism; D019698:Hepatitis C, Chronic / Q000150:complications / Q000378:metabolism; D006801:Humans; D016898:Interferon-alpha / Q000627:therapeutic use*; D008099:Liver / Q000737:chemistry*; D008103:Liver Cirrhosis / Q000188:drug therapy* / Q000209:etiology / Q000378:metabolism; D008111:Liver Function Tests; D009682:Magnetic Resonance Spectroscopy; D008297:Male; D008875:Middle Aged; D010714:Phosphatidylethanolamines / Q000032:analysis*; D010759:Phosphorus Isotopes; D010767:Phosphorylcholine / Q000032:analysis*; D011092:Polyethylene Glycols / Q000627:therapeutic use*; D012367:RNA, Viral / Q000097:blood; D011994:Recombinant Proteins / Q000627:therapeutic use; D012254:Ribavirin / Q000627:therapeutic use*
chemical_list: D000998:Antiviral Agents; D004983:Ethanolamines; D016898:Interferon-alpha; D010714:Phosphatidylethanolamines; D010759:Phosphorus Isotopes; D012367:RNA, Viral; D011994:Recombinant Proteins; D010767:Phosphorylcholine; C002449:glycerophosphoethanolamine; D011092:Polyethylene Glycols; D012254:Ribavirin; D005997:Glycerylphosphorylcholine; C005448:phosphorylethanolamine; D000255:Adenosine Triphosphate; C100416:peginterferon alfa-2a